IGF-1 LR3

IGF-1 LR3 (Long R3 Insulin-like Growth Factor-1) is a synthetic, recombinant analogue of human IGF-1 engineered with two modifications: an arginine substitution at position 3 and a 13-amino-acid N-terminal extension. These changes prevent binding to IGF-binding proteins (IGFBPs) that normally sequester and inactivate circulating IGF-1, dramatically extending its effective half-life from minutes to 20–30 hours. IGF-1 LR3 is one of the most anabolic compounds studied in muscle biology research, with potent effects on satellite cell activation, protein synthesis, nitrogen retention, and hyperplasia (the formation of new muscle fibers — not merely enlargement of existing ones).

IGF-1 LR3 binds and activates IGF-1 receptors (IGF-1R) and insulin receptors throughout the body, particularly in skeletal muscle, liver, bone, and adipose tissue. IGF-1R activation triggers the PI3K/Akt/mTOR signaling cascade — the master anabolic signaling network governing protein synthesis, cellular growth, and anti-apoptotic survival. Additionally, IGF-1R activates the Ras/ERK MAPK pathway, driving cellular proliferation. Most significantly for muscle research, IGF-1 LR3 potently activates satellite cells — the muscle stem cells that fuse with existing fibers to create new myonuclei (myonuclear accretion) or fuse together to form entirely new muscle fibers (hyperplasia). This hyperplastic effect on muscle tissue — adding new fibers rather than just increasing fiber size — is considered the holy grail of muscle growth research and distinguishes IGF-1 LR3 from GH or anabolic steroids, which primarily promote hypertrophy of existing fibers. IGF-1 LR3's inability to bind IGFBPs is the key feature that keeps it biologically active in tissue for its full 20–30 hour half-life.

IGF-1 LR3 was engineered to address the short plasma half-life (~10 minutes) of native IGF-1 due to IGFBP binding. Pharmacokinetic studies confirmed the 20–30 hour half-life of LR3 vs native IGF-1. Research in muscle biology confirmed potent satellite cell activation and myonuclear accretion in rodent models, with evidence of true hyperplasia (new fiber formation) at higher doses — not observed with anabolic steroids. Studies in cancer cell lines identified concerns about IGF-1R-mediated tumor cell proliferation, providing the basis for its classification as an advanced research compound. Hypoglycemia as the primary acute risk was established in early dose-escalation studies. It has been used extensively as a research tool to study IGF-1 receptor biology and the GH/IGF-1 axis.

Post-Workout Muscle Hyperplasia Protocol: 40–60 mcg IM into trained muscles within 30 minutes of workout, daily for 4 weeks, followed by 8 weeks off. Systemic Anabolic Protocol: 50–80 mcg SC in the abdomen daily for 4–6 weeks. Always have glucose source available during use. Not recommended as a beginner compound due to hypoglycemia risk and need for precise management. Best used by experienced researchers with access to blood glucose monitoring.

Hypoglycemia is the most significant acute risk of IGF-1 LR3 and must be managed carefully. Symptoms of hypoglycemia — shakiness, sweating, confusion, rapid heartbeat — can occur 20–60 minutes post-injection and should be treated immediately with fast-acting carbohydrates. This risk is why IGF-1 LR3 should always be dosed away from meals and never combined with insulin. Joint pain, particularly in the jaw, wrists, and ankles, is common at higher doses and reflects the potent anabolic effect on cartilage and connective tissue. Water retention and swelling in the extremities can occur. Organ growth (organomegaly) — particularly the heart, intestines, and liver — is a theoretical concern with chronic supraphysiological IGF-1 signaling. GH-related side effects (numbness, tingling, carpal tunnel-like symptoms) appear at higher doses. Long-term elevated IGF-1 signaling is a recognized risk factor for certain cancers, making cycles, off periods, and avoidance in individuals with cancer history essential.

Store lyophilized IGF-1 LR3 at -80°C for maximum stability (up to 36 months) or at -20°C for up to 12 months. Short-term storage at 2–8°C is stable for up to 30 days. Once reconstituted with 0.1% acetic acid (preferred for IGF-1 LR3) or bacteriostatic water, store at 2–8°C and use within 14 days. IGF-1 LR3 is a large, delicate protein peptide — handle with care. Never vortex or shake vigorously; gently swirl to dissolve. Avoid plastic pipettes (it adsorbs to plastic) — use glass or silicone-coated tips where possible.